CO2020000227A2 - Moduladores de nlrp3 - Google Patents
Moduladores de nlrp3Info
- Publication number
- CO2020000227A2 CO2020000227A2 CONC2020/0000227A CO2020000227A CO2020000227A2 CO 2020000227 A2 CO2020000227 A2 CO 2020000227A2 CO 2020000227 A CO2020000227 A CO 2020000227A CO 2020000227 A2 CO2020000227 A2 CO 2020000227A2
- Authority
- CO
- Colombia
- Prior art keywords
- nlrp3
- modulators
- nlrp3 modulators
- compounds
- variables
- Prior art date
Links
- 101150061038 NLRP3 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Amplifiers (AREA)
- Burglar Alarm Systems (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invención proporciona compuestos de la Fórmula (I): (I) en donde todas las variables son como se definen en la presente. Estos compuestos son moduladores de NLRP3, que se pueden utilizar como medicamentos para el tratamiento contra trastornos proliferativos, tales como cáncer en un sujeto (por ejemplo, un ser humano).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762532932P | 2017-07-14 | 2017-07-14 | |
US201862662405P | 2018-04-25 | 2018-04-25 | |
US201862689412P | 2018-06-25 | 2018-06-25 | |
PCT/US2018/041723 WO2019014402A1 (en) | 2017-07-14 | 2018-07-12 | MODULATORS OF NLRP3 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020000227A2 true CO2020000227A2 (es) | 2020-01-17 |
Family
ID=63036509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0000227A CO2020000227A2 (es) | 2017-07-14 | 2020-01-10 | Moduladores de nlrp3 |
Country Status (16)
Country | Link |
---|---|
US (2) | US11344543B2 (es) |
EP (1) | EP3652166A1 (es) |
JP (1) | JP7159282B2 (es) |
KR (1) | KR20200028434A (es) |
CN (2) | CN110914258A (es) |
AU (1) | AU2018301681B2 (es) |
BR (1) | BR112020000523A2 (es) |
CA (1) | CA3069524A1 (es) |
CL (1) | CL2020000085A1 (es) |
CO (1) | CO2020000227A2 (es) |
IL (1) | IL271935A (es) |
NZ (1) | NZ761519A (es) |
PE (1) | PE20200296A1 (es) |
SG (1) | SG11202000248UA (es) |
TW (1) | TWI791556B (es) |
WO (1) | WO2019014402A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022517112A (ja) * | 2019-01-14 | 2022-03-04 | イネイト・テューマー・イミュニティ・インコーポレイテッド | Nlrp3モジュレーター |
WO2020150115A1 (en) * | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
CN113195469B (zh) * | 2019-02-19 | 2024-05-24 | 四川科伦博泰生物医药股份有限公司 | 含氮并环化合物、其制备方法及用途 |
CN114555565B (zh) * | 2019-12-13 | 2024-03-05 | 四川科伦博泰生物医药股份有限公司 | 含氮并环化合物、其制备方法及用途 |
KR20230019101A (ko) | 2020-04-29 | 2023-02-07 | 상하이 린진 바이오파마 씨오., 엘티디. | 벤조티아졸릴 비아릴 화합물, 제조 방법 및 용도 |
WO2022017408A1 (zh) * | 2020-07-22 | 2022-01-27 | 中国医药研究开发中心有限公司 | 芳胺类衍生物及其制备方法和医药用途 |
KR102409345B1 (ko) * | 2020-09-22 | 2022-06-16 | 가톨릭대학교 산학협력단 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4075343A (en) * | 1976-09-13 | 1978-02-21 | Pfizer Inc. | Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof |
JPS5390271A (en) * | 1977-01-14 | 1978-08-08 | Pfizer | Method of producing 22aminoo44hydroxyquinoline |
US4247699A (en) * | 1979-03-14 | 1981-01-27 | Pfizer Inc. | Process for making 2-amino-4-hydroxyquinolines |
GB8727737D0 (en) * | 1987-11-26 | 1987-12-31 | Ici Plc | Antitumour agents |
JPH11209350A (ja) * | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | 含窒素複素環誘導体およびその医薬 |
EP2112166B1 (en) | 1998-12-23 | 2018-11-21 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
DE60033530T2 (de) | 1999-08-24 | 2007-10-31 | Medarex Inc. | Humane antikörper gegen ctla-4 und deren verwendungen |
DE60225274T2 (de) * | 2001-05-21 | 2009-03-26 | F. Hoffmann-La Roche Ag | Chinolinderivate als liganden für den neuropeptid-y-rezeptor |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US6818772B2 (en) * | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
CN1678586A (zh) * | 2002-06-27 | 2005-10-05 | 舍林股份公司 | 取代的喹啉ccr5受体拮抗剂 |
ES2925655T3 (es) * | 2003-09-26 | 2022-10-19 | Exelixis Inc | Moduladores c-Met y métodos de uso |
BRPI0613361A2 (pt) | 2005-07-01 | 2011-01-04 | Medarex Inc | anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1 |
EP1917245A1 (de) * | 2005-08-21 | 2008-05-07 | Abbott GmbH & Co. KG | Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
MX2008009475A (es) * | 2006-01-23 | 2008-10-20 | Amira Pharmaceuticals Inc | Inhibidores triciclicos de 5-lipoxigenasa. |
US7868022B2 (en) * | 2006-02-06 | 2011-01-11 | Janssen Pharmaceutica Nv | 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
AR065093A1 (es) * | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
CA2713998A1 (en) * | 2008-01-28 | 2009-08-06 | Janssen Pharmaceutica N.V. | 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of.beta.-secretase (bace) |
WO2009097401A1 (en) * | 2008-01-29 | 2009-08-06 | Janssen Pharmaceutica N.V. | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
WO2010092340A1 (en) * | 2009-02-13 | 2010-08-19 | Ucb Pharma S.A. | Fused pyridine and pyrazine derivatives as kinase inhibitors |
WO2011063233A1 (en) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
WO2011063272A1 (en) * | 2009-11-23 | 2011-05-26 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
BR122021025338B1 (pt) | 2009-11-24 | 2023-03-14 | Medimmune Limited | Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos |
US8735384B2 (en) * | 2010-01-19 | 2014-05-27 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
WO2012037108A1 (en) | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | B7-h1 및 pd-1과 결합하는 항체 및 다른 분자들 |
HUE051954T2 (hu) | 2011-11-28 | 2021-03-29 | Merck Patent Gmbh | ANTI-PD-L1 ellenanyagok és alkalmazásaik |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
WO2013181634A2 (en) | 2012-05-31 | 2013-12-05 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind pd-l1 |
DK2992017T3 (da) | 2013-05-02 | 2021-01-25 | Anaptysbio Inc | Antistoffer rettet mod programmeret død-1 (pd-1) |
MX354057B (es) | 2013-05-18 | 2018-02-09 | The Regents Of The Univ Of California Star | Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón". |
CN111423511B (zh) | 2013-05-31 | 2024-02-23 | 索伦托药业有限公司 | 与pd-1结合的抗原结合蛋白 |
CN107011441B (zh) | 2013-09-13 | 2020-12-01 | 百济神州(广州)生物科技有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
CA2922542A1 (en) * | 2013-11-22 | 2015-05-28 | University Of Kentucky Research Foundation | Arylquinoline and analog compounds and use thereof to treat cancer |
PT3081576T (pt) | 2013-12-12 | 2019-10-15 | Jiangsu Hengrui Medicine Co | Anticorpo pd-1, fragmento de ligação ao antigénio do mesmo e aplicação médica do mesmo |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
ES2881228T3 (es) | 2015-02-16 | 2021-11-29 | Univ Queensland | Sulfonilureas y compuestos relacionados y uso de los mismos |
MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
US20160332971A1 (en) * | 2015-05-15 | 2016-11-17 | University Of Kentucky Research Foundation | Arylquinoline, arylquinolone and arylthioquinolone derivatives and use thereof to treat cancer |
PT3303394T (pt) | 2015-05-29 | 2020-07-01 | Ludwig Inst For Cancer Res Ltd | Anticorpos anti-ctla-4 e métodos de uso dos mesmos |
WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
EP3337481B1 (en) * | 2015-08-21 | 2020-11-11 | The University of Kansas | Quinoline-2-amine derivatives as human tlr8-selective agonists for increasing immune response |
AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
CN108289912A (zh) | 2015-09-01 | 2018-07-17 | 先天肿瘤免疫公司 | 具有提高的免疫力或免疫抑制性细胞因子抗性的免疫细胞及其用途 |
KR20220131277A (ko) | 2015-09-01 | 2022-09-27 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
WO2017132825A1 (zh) | 2016-02-02 | 2017-08-10 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
WO2017184735A1 (en) | 2016-04-19 | 2017-10-26 | Ifm Therapeutics, Inc | Nlrp3 modulators |
BR112018071347A2 (pt) | 2016-04-19 | 2019-02-05 | Innate Tumor Immunity Inc | moduladores de nlrp3 |
AU2017382830A1 (en) * | 2016-12-19 | 2019-06-13 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as EHMT2 inhibitors and methods of use thereof |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
-
2018
- 2018-07-12 AU AU2018301681A patent/AU2018301681B2/en active Active
- 2018-07-12 PE PE2020000051A patent/PE20200296A1/es unknown
- 2018-07-12 BR BR112020000523-1A patent/BR112020000523A2/pt active Search and Examination
- 2018-07-12 SG SG11202000248UA patent/SG11202000248UA/en unknown
- 2018-07-12 KR KR1020207003984A patent/KR20200028434A/ko not_active Application Discontinuation
- 2018-07-12 US US16/629,980 patent/US11344543B2/en active Active
- 2018-07-12 JP JP2020501154A patent/JP7159282B2/ja active Active
- 2018-07-12 NZ NZ761519A patent/NZ761519A/en unknown
- 2018-07-12 CN CN201880046886.XA patent/CN110914258A/zh active Pending
- 2018-07-12 CA CA3069524A patent/CA3069524A1/en active Pending
- 2018-07-12 CN CN202010596091.5A patent/CN111793060B/zh active Active
- 2018-07-12 EP EP18746537.2A patent/EP3652166A1/en active Pending
- 2018-07-12 WO PCT/US2018/041723 patent/WO2019014402A1/en unknown
- 2018-07-13 TW TW107124243A patent/TWI791556B/zh active
-
2020
- 2020-01-09 IL IL271935A patent/IL271935A/en unknown
- 2020-01-10 CL CL2020000085A patent/CL2020000085A1/es unknown
- 2020-01-10 CO CONC2020/0000227A patent/CO2020000227A2/es unknown
-
2022
- 2022-04-28 US US17/731,279 patent/US20220257587A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3652166A1 (en) | 2020-05-20 |
AU2018301681A1 (en) | 2020-02-27 |
CL2020000085A1 (es) | 2020-07-10 |
WO2019014402A1 (en) | 2019-01-17 |
CN110914258A (zh) | 2020-03-24 |
CA3069524A1 (en) | 2019-01-17 |
US20200129500A1 (en) | 2020-04-30 |
PE20200296A1 (es) | 2020-02-06 |
AU2018301681B2 (en) | 2022-07-14 |
CN111793060B (zh) | 2023-06-06 |
KR20200028434A (ko) | 2020-03-16 |
JP2020527139A (ja) | 2020-09-03 |
IL271935A (en) | 2020-02-27 |
US11344543B2 (en) | 2022-05-31 |
JP7159282B2 (ja) | 2022-10-24 |
SG11202000248UA (en) | 2020-02-27 |
BR112020000523A2 (pt) | 2020-07-14 |
NZ761519A (en) | 2023-07-28 |
CN111793060A (zh) | 2020-10-20 |
TW201908304A (zh) | 2019-03-01 |
TWI791556B (zh) | 2023-02-11 |
US20220257587A1 (en) | 2022-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021006672A2 (es) | Moduladores de nlrp3 | |
CO2020000227A2 (es) | Moduladores de nlrp3 | |
CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CL2018000150A1 (es) | Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508) | |
CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
CU20160185A7 (es) | Compuestos de heteroarilo para la inhibición de cinasa | |
ECSP16073190A (es) | Ciclopropilaminas como inhibidores de lsd1 | |
CO2017005959A2 (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
UY36077A (es) | Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen | |
CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
CO2019013016A2 (es) | Inhibidores pirazólicos de magl | |
CO2021014008A2 (es) | Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento | |
NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
CL2019003515A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina. | |
CL2017001539A1 (es) | Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos | |
ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
CL2020001093A1 (es) | Proceso para preparar el benzotiofen-2-il boronato. | |
DOP2017000196A (es) | Derivados de tetrahidropiranil benzamida | |
AR107460A1 (es) | Gabapentina oftálmica para el tratamiento de las úlceras corneales | |
ECSP16094286A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
EA202090283A1 (ru) | Модуляторы nlrp3 | |
EA202092539A1 (ru) | Модуляторы nlrp3 |